The ACEIs have been shown in randomized,
controlled, clinical trials to decrease mortality and morbidity
in congestive heart failure after recent and remote
myocardial infarction, blunt the decline in glomerular filtration
rate, reduce incidence of stroke, produce greater regression
of left ventricular hypertrophy than non–RAAS-blocking
therapies, reduce albuminuria, delay the onset of new
diabetes, and improve endothelial function (see Cushman41
for review).